Trial
NCT03710421
CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma
Phase ISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Condition
Recurrent Plasma Cell Myeloma
Intervention
CS1-CAR T Therapy
Why stopped
Slow/Low Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-01